Naphthyl Ring System Patents (Class 568/328)
  • Patent number: 10189991
    Abstract: Compositions and methods for a melt processable semicrystalline poly(aryl ether ketone) incorporating phthalazinone and 4,4?-biphenol as comonomer units are described herein. The polymers are resistant to and insoluble in common organic solvents and liquids as well as in aggressive organic solvents such as chloroform and chlorinated liquids. The polymers are melt processable via techniques such as extrusion, injection molding, and compression molding. The semicrystalline poly(aryl ether ketone) containing phthalazinone comonomer units have properties which make them suitable for manufacturing high temperature resistant molded systems and other articles.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: January 29, 2019
    Assignee: Polymics, LTD
    Inventors: Tim Hsu, Yi-Feng Wang, Allan S. Hay
  • Publication number: 20150141415
    Abstract: The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivatives thereof or a pharmaceutical salts thereof.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 21, 2015
    Inventors: Omonike Arike Olaleye, Sarah Finney John, Adaugo Chimzurum Isichei, Jun O Liu, Rosa Maldonado, Janice Endsley
  • Patent number: 9005478
    Abstract: A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C?O)R9, —(C?O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; R3 is hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R4 is hydrogen, alkyl, aryl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R5, R6, R7, and R8 are independently hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, alkoxyaryl or heterocyclic all either substituted or unsubstituted, or combine with each other, or R5 can combine with R4 to form a carbocyclic or heterocyclic ring; R9 and R10 are independently alkyl, alkoxy, aryl, naphthyl, styryl, alkenyl, cycloalkyl, alko
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: April 14, 2015
    Assignees: Kent Displays Incorporated, Kent State University
    Inventors: Donald R. Diehl, Erica N. Montbach
  • Publication number: 20150073177
    Abstract: Methods are provided to inhibit proliferation of Trypanosoma cruzi with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can be used to provide prophylaxis or treatment to a patient in need of treatment against Chagas disease.
    Type: Application
    Filed: July 27, 2012
    Publication date: March 12, 2015
    Applicant: HOWARD UNIVERRSITY
    Inventors: Oladapo Bakare, Clarence M. Lee, Yakini Brandy, Mozna Husein Khraiwesh
  • Publication number: 20150031867
    Abstract: The present invention provides a water-soluble fluorescent compound of resveratrone 6-O-?-glucoside [(E)-4-(8-hydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)naphthalen-2-yl)but-3-en-2-one] and its derivatives of Formula 1 which have at least one water-soluble substituent, and a method for preparing the same by a photochemical reaction of resveratrol 3-O-?-glucoside and its derivatives of having Formula 3 which are not fluorescent. Said new water-soluble fluorescent compounds has single-photon absorptive characteristics and/or two-photon absorptive characteristics as well as no or little toxicity, and can be usefully utilized in fields that requires water-soluble fluorescent characteristics (diagnosis, fluorescent probe, in vivo imaging, display, etc.).
    Type: Application
    Filed: September 5, 2012
    Publication date: January 29, 2015
    Inventors: Seong Keun Kim, Seung Yang, Seon JIn Hwang, Jung Eun Lee, Jong Woo Lee, Jun Hee Kang, Eun Hak Lim
  • Publication number: 20150018566
    Abstract: The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene.
    Type: Application
    Filed: August 27, 2012
    Publication date: January 15, 2015
    Inventors: John Jarlath Walsh, Richard Shah, Emmet Martin McCormack, Gillian Joy Hudson, Martina White, Gary Daniel Stack, Brian William Moran, Adrian Coogan, Elaine Carmel Breen
  • Patent number: 8895624
    Abstract: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use in the treatment of osteoporosis and/or osteopenia.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: November 25, 2014
    Assignee: Haoma Medica Ltd.
    Inventors: Stephen Hodges, Robin Soper
  • Patent number: 8877718
    Abstract: The present invention relates to naphthoquinone derivatives isolated from solid callus cultures from two species of the palaeotropical plant families Dioncophyllaceae and Ancistrocladaceae. It further relates to methods of their production as well as to their use as antiinfective and antitumoral pharmaceuticals.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: November 4, 2014
    Assignee: Julius-Maximilians-Universität Würzburg
    Inventors: Gerhard Bringmann, Stefan Rüdenauer, Reto Brun, Andreas Irmer, Ralf Bargou, Manik Chatterjee, Anastasia Voskobojnik
  • Publication number: 20140221319
    Abstract: The invention provides methods and compositions for inhibiting CD 38 activity, and methods of treating or preventing various disorders associated with CD38 activity.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 7, 2014
    Applicants: Mayo Foundation for Medical Education and Research, President and Fellows of Harvard College
    Inventors: David A. Sinclair, Nathan L. Price, Eduardo N. Chini, Jon C. Clardy, Shugeng Cao
  • Publication number: 20140186328
    Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.
    Type: Application
    Filed: February 5, 2014
    Publication date: July 3, 2014
    Applicant: Salk Institute for Biological Studies
    Inventors: David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
  • Patent number: 8765719
    Abstract: An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: July 1, 2014
    Assignee: Kagoshima University
    Inventors: Masanori Baba, Yuichi Hashimoto
  • Publication number: 20140121238
    Abstract: Naphthoquinones, azanaphthoquinones and benxanthones, their process of synthesis and methods of their use as antimalarial or antischistosomal agents.
    Type: Application
    Filed: March 29, 2012
    Publication date: May 1, 2014
    Applicant: Centre National De La Recherche Scientifique
    Inventors: Elisabeth Davioud-Charvet, Don Antoine Lanfranchi, Laure Johann, David Lee Williams, Elena Cesar Rodo
  • Patent number: 8709281
    Abstract: A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C?O)R9, —(C?O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; and R3-R9 are as described in the disclosure. Also featured are liquid crystal compositions comprising a chiral dopant compound represented by any of Structure 2-4 as described in the disclosure.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: April 29, 2014
    Assignee: Kent State University
    Inventors: Donald R. Diehl, Erica N. Montbach
  • Patent number: 8692023
    Abstract: The purpose of the present invention is to provide a highly safe composition that improves glucose tolerance and sugar metabolism at skeletal muscles, and a prevention/treatment drug for diabetes/metabolic syndrome containing the composition. Provided is a composition that is for improving sugar metabolism and glucose tolerance and that contains a compound represented by formula (I) derived from a plant selected from the group consisting of Rumex japonicus, R. crispus, and R. obtusifolius as the active ingredient.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: April 8, 2014
    Assignee: Erina Co., Inc.
    Inventors: Takayuki Yonezawa, Je-Tae Woo, Kazumi Yagasaki
  • Publication number: 20140012015
    Abstract: The present invention provides a process for preparing a bicyclic amine derivative of the formula (Ia) or (Ib), comprising the rhodium-catalyzed asymmetric hydrogenation of an enamine of the formula (II), in the presence of a chiral ligand, wherein the chiral ligand is a chiral phosphine ligand.
    Type: Application
    Filed: July 2, 2013
    Publication date: January 9, 2014
    Inventors: Yi-Yin Ku, Steven Hannick, Ashok K. Gupta
  • Patent number: 8598387
    Abstract: Disclosed herein is novel process for preparation of atovaquone, which process includes reacting 1H-2-benzopyran-1,4(3H)-dione with 4-(4-chlorophenyl)cyclohexanecarbaldehyde. The invention further discloses novel intermediates useful in the preparation of atovaquone.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: December 3, 2013
    Assignee: Glaxo Group Limited
    Inventors: Andrew Neil Dwyer, Andrew Gordon, Michael Urquhart
  • Publication number: 20130245325
    Abstract: The purpose of the present invention is to provide a highly safe composition that improves glucose tolerance and sugar metabolism at skeletal muscles, and a prevention/treatment drug for diabetes/metabolic syndrome containing the composition. Provided is a composition that is for improving sugar metabolism and glucose tolerance and that contains a compound represented by formula (I) derived from a plant selected from the group consisting of Rumex japonicus, R. crispus, and R. obtusifolius as the active ingredient.
    Type: Application
    Filed: January 18, 2013
    Publication date: September 19, 2013
    Applicant: ERINA CO., INC.
    Inventors: Takayuki YONEZAWA, Je-Tae WOO, Kazumi YAGASAKI
  • Patent number: 8524952
    Abstract: A modified dimethylnaphthalene formaldehyde resin obtained by modifying a polyfunctional dimethylnaphthalene formaldehyde resin having a constituent unit represented by the following general formula [1] in a molecule thereof with at least one member selected from the group consisting of a phenol represented by the following general formula [2], a naphthol represented by the following general formula [3] and a naphthol represented by the following general formula [4] provided that at least any of the naphthol represented by the general formula [3] or the naphthol represented by the general formula [4] must be included.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: September 3, 2013
    Assignee: Mitsubishi Gas Chemical Company, Inc.
    Inventors: Seiji Kita, Masashi Ogiwara, Mitsuharu Kitamura, Dai Oguro, Gou Higashihara
  • Publication number: 20130225690
    Abstract: The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.
    Type: Application
    Filed: September 20, 2012
    Publication date: August 29, 2013
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Roman Perez-Soler, Yi-He Ling
  • Publication number: 20130137640
    Abstract: A composition includes a food ingredient or nutrient with safety and experience having been eaten for a long time and that shows a collagen enhancing activity. The food ingredient or nutrient of the composition includes a skin collagen enhancing agent that includes menaquinone-7 as an active ingredient. The composition including skin collagen enhancing agent can be administered percutaneously or orally as a drug, a cosmetic, or a supplement.
    Type: Application
    Filed: October 3, 2012
    Publication date: May 30, 2013
    Applicant: J-OIL MILLS, INC.
    Inventor: J-OIL MILLS, INC.
  • Publication number: 20130123367
    Abstract: The present invention relates to vinylogous chalcone derivatives, in particular the compounds of formula (I) as described and defined herein, pharmaceutical compositions comprising these compounds, and their medical use, including their use in the treatment or prevention of cancer, in particular malignant hematological diseases/disorders.
    Type: Application
    Filed: July 27, 2011
    Publication date: May 16, 2013
    Applicant: MEDIZINISCHE UNIVERSITAT WIEN
    Inventors: Thomas Erker, Gerda Brunhofer, Ulrich Jäger, Katrina Vanura, Verena Dirsch, Elke Heiss
  • Patent number: 8436207
    Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: May 7, 2013
    Assignee: Burnham Institute for Medical Research
    Inventor: Maurizio Pellecchia
  • Publication number: 20130102498
    Abstract: Novel substrates for detection of activity of amyloid beta degrading enzyme, such as Neprilysin (NEP) and insulin degrading enzyme (IDE), associated with Alzheimer's disease, are provided. A quenched fluorogenic peptide substrate containing the first seven residues of the A?peptide plus a C-terminal Cys residue to detect neprilysin activity with a fluorophore attached to the C-terminal Cys and a quencher linked to the N-terminus of the peptide is disclosed. An assay system sensitive to endopeptidase activity of NEP and IDE, but insensitive to other A?-degrading enzymes is disclosed. Active compounds are identified by a cell-based assay system for high-throughput screening.
    Type: Application
    Filed: May 8, 2012
    Publication date: April 25, 2013
    Applicant: ACADEMIA SINICA
    Inventors: Rita P.-Y. Chen, Steven Sheng-Shih Wang, Chaur-Jong Hu, Po-Ting CHEN
  • Publication number: 20130096175
    Abstract: Provided are compounds which generally have a triketone structure. Examples of the compounds include derivatives of 1,3-cyclohexanedione, such as: 1,3-cyclohexanedione, 2-propanoyl-5-cyclohexyl-; 1,3-cyclohexanedione, 2-propanoyl-5-[4-fluorophenyl]-; 1,3-cyclohexanedione, 2-acetyl-5-[thien-2-yl]-; 1,3-cyclohexanedione, 2-acetyl-5-butyl-; and 1,3-cyclohexanedione, 2-propanoyl-5-[bicyclo[2.2.1]hept-2-en-5-yl]-. The compounds can be used to alter the lifespan of eukaryotic organisms and treat inflammation.
    Type: Application
    Filed: November 17, 2010
    Publication date: April 18, 2013
    Applicants: SOUTHERN RESEARCH INSTITUTE, UNIVERSITY OF ROCHESTER
    Inventors: David S. Goldfarb, Joseph A. Maddry, Lynn Rasmussen, Ellie Lucile White, Krister Wennerberg
  • Publication number: 20130030050
    Abstract: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use in the treatment of osteoporosis and/or osteopenia.
    Type: Application
    Filed: December 22, 2010
    Publication date: January 31, 2013
    Applicant: Haoma Medica Limited
    Inventors: Stephen Hodges, Robin Soper
  • Publication number: 20130018026
    Abstract: The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided.
    Type: Application
    Filed: July 13, 2012
    Publication date: January 17, 2013
    Inventor: Keith R. Latham
  • Publication number: 20120322107
    Abstract: The invention encompasses the use of one or more compounds selected from a list comprising i) reduced forms of vitamin K and/or ii) reduced forms of a vitamin K analog and/or iii) reduced forms of a vitamin K precursor for the expression of one or more functional vitamin K-dependent proteins in cell culture as well as processes for the fermentation of eucaryotic cells expressing one or more vitamin K-dependent proteins wherein one or more compounds selected from a list comprising i) reduced forms of vitamin K and/or ii) reduced forms of a vitamin K analog and/or iii) reduced forms of a vitamin K precursor are added to the cell culture medium before and/or during the fermentation process.
    Type: Application
    Filed: July 9, 2010
    Publication date: December 20, 2012
    Applicant: CSL LIMITED
    Inventors: Julian Keane, Anthony Stowers, Peter Soupourmas, Fraser Goodwin
  • Patent number: 8314045
    Abstract: A porous solid acid catalyst having high concentration of acidic sites and a large surface area includes a porous silica support and a sulfonated carbon layer disposed within the pores of the silica support. The catalyst, in certain embodiments, has a concentration of —SO3H groups of at least about 0.5 mmol/g and a predominant pore size of at least about 300 ?. The catalyst is used to catalyze a variety of acid-catalyzed reactions, including but not limited to alkylation, acylation, etherification, olefin hydration and alcohol dehydration, dimerization of olefin and bicyclic compounds, esterification and transesterification. For example, the catalyst can be used to catalyze esterification of free fatty acids (FFAs) and, in certain embodiments, to catalyze transesterification of triglycerides in fats and oils.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: November 20, 2012
    Assignee: Entreprises Sinoncelli S.A.R.L.
    Inventors: Jacques Sinoncelli, Sergey V. Gurevich
  • Publication number: 20120264942
    Abstract: Provided is a compound found by screening a material for inhibiting an osteopontin, in which the material for inhibiting the osteopontin can increase effectiveness as an excellent material for inhibiting an osteoporosis.
    Type: Application
    Filed: November 14, 2011
    Publication date: October 18, 2012
    Applicant: INNOPHARMASCREEN, INC.
    Inventors: In-Cheol Kang, Eung-Yoon Kim, Young-Jin Choi
  • Publication number: 20120264765
    Abstract: The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds.
    Type: Application
    Filed: October 29, 2010
    Publication date: October 18, 2012
    Applicants: Cambria Pharmaceuticals, Inc., Northwestern University
    Inventors: Donald R. Kirsch, Radhia Benmohamed, Anthony C. Arvanties, Richard I. Morimoto, Wei Zhang, Richard B. Silverman
  • Patent number: 8283499
    Abstract: The present invention relates the use of 2,3-dihalonaphthoquinone compounds of Formula I wherein R1 and R2 are leaving groups like halogens selected from the group comprising Cl, Br, I and F and the R1 and R2 may be the same halogen or may contain different halogen groups, or sulphonyl groups, for making napthoquinone compounds of Formula IA wherein X is any aryl, heteroaryl, alkyl, cyclohexyl, substituted cylohexyl groups and the like.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: October 9, 2012
    Assignee: Alkem Laboratories Limited
    Inventors: Sanjay Sukumar Saralya, Shashikumar Hiriyalu Somashekar, Shashiprabha, Shridhara Kanakamajalu, Koottungalmadhom Ramaswamy Ranganathan, Veerasamy Ananthalakshmi, Govindarajalu Jeyaraman, Kothapalli Sundarraja Rao, Kuppuswamy Nagarajan
  • Publication number: 20120238781
    Abstract: A modified dimethylnaphthalene formaldehyde resin obtained by modifying a polyfunctional dimethylnaphthalene formaldehyde resin having a constituent unit represented by the following general formula [1] in a molecule thereof with at least one member selected from the group consisting of a phenol represented by the following general formula [2], a naphthol represented by the following general formula [3] and a naphthol represented by the following general formula [4] provided that at least any of the naphthol represented by the general formula [3] or the naphthol represented by the general formula [4] must be included.
    Type: Application
    Filed: March 19, 2012
    Publication date: September 20, 2012
    Applicant: Mitsubishi Gas Chemical Company, Inc.
    Inventors: Seiji Kita, Masashi Ogiwara, Mitsuharu Kitamura, Dai Oguro, Gou Higashihara
  • Patent number: 8212079
    Abstract: The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a chloride salt of an active pharmaceutical ingredient. The present disclosure also relates to methods of preparing cocrystals and methods for screening for solid state phases.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: July 3, 2012
    Assignee: Aptuit (West Lafayette), LLC
    Inventor: Scott L. Childs
  • Publication number: 20120077986
    Abstract: The present invention is directed to provide a novel preparation of anticancer-active tricyclic compounds via alkyne coupling reaction. The present invention provides a process for preparing a compound of formula (Ia) or (Ib): wherein R1 is optionally substituted C1-6 alkyl, etc.; W is O, S or NR2; R2 is hydrogen atom, etc., which comprises Step (a) in which a compound of formula (II): wherein R1 is the same as defined above, and a compound of formula (III) or (IV): wherein R2 is the same as defined above; R3 is hydrogen atom, etc.; X is halogen atom, etc., are reacted in the presence of a base, a copper catalyst and a palladium catalyst in an aprotic polar solvent.
    Type: Application
    Filed: July 26, 2011
    Publication date: March 29, 2012
    Applicant: TAHEEBO JAPAN CO., LTD.
    Inventors: Akira IIDA, Kazunori UEDA, Mitsuaki YAMASHITA
  • Publication number: 20120046320
    Abstract: The present invention discloses ?-diketones, ?-diketones or ?-hydroxyketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
    Type: Application
    Filed: August 17, 2011
    Publication date: February 23, 2012
    Applicant: WINTHERIX, LLC
    Inventors: Sunil Kumar KC, David Mark Wallace, John Hood, Charlene F. Barroga
  • Publication number: 20120015992
    Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
    Type: Application
    Filed: September 21, 2011
    Publication date: January 19, 2012
    Applicant: Burnham Institute for Medical Research
    Inventor: Maurizio Pellecchia
  • Publication number: 20110257047
    Abstract: Methods for labeling a substrate using a hetero-Diels-Alder reaction are disclosed. The hetero-Diels-Alder reaction includes the reaction of an o-quinone methide (e.g., an o-naphthoquinone methide) with a polarized olefin to form a hetero-Diels-Alder adduct. The o-quinone methide or the polarized olefin can be attached to a surface of a substrate, and the other of the o-quinone methide or the polarized olefin can include a detectable label. The o-quinone methide can conveniently be generated by irradiation of a precursor compound, preferably in an aqueous solution, suspension, or dispersion.
    Type: Application
    Filed: May 5, 2011
    Publication date: October 20, 2011
    Inventors: Vladimir V. Popik, Selvanathan Arumugam
  • Publication number: 20110257430
    Abstract: The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a chloride salt of an active pharmaceutical ingredient. The present disclosure also relates to methods of preparing cocrystals and methods for screening for solid state phases.
    Type: Application
    Filed: June 28, 2011
    Publication date: October 20, 2011
    Applicant: APTUIT (KANSAS CITY), LLC
    Inventor: Scott L. CHILDS
  • Patent number: 8039668
    Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: October 18, 2011
    Assignee: Burnham Institute for Medical Research
    Inventor: Maurizio Pellecchia
  • Patent number: 8022095
    Abstract: The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1B/1D agonist.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: September 20, 2011
    Assignee: Pozen, Inc.
    Inventor: John R. Plachetka
  • Publication number: 20110172185
    Abstract: An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.
    Type: Application
    Filed: August 22, 2009
    Publication date: July 14, 2011
    Inventors: Masanori Baba, Yuichi Hashimoto
  • Patent number: 7951844
    Abstract: This invention provides a pharmaceutical and functional food which are made of a safe food ingredient or nutrient which has been used for a long period of time, and which have tranquilizing effect such as anti-anxiety effect, anti-depression effect, and anti-stress effect. The tranquilizer of the invention contains vitamin K as an active ingredient. Vitamin K is preferably menaquinone-4 and/or menaquinone-7. This invention also provides a supplement, health food or functional food for tranquilizing purpose that contains vitamin K as an active ingredient.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: May 31, 2011
    Assignee: J-Oil Mills, Inc.
    Inventors: Toshiro Sato, Shuichi Kamo, Rumi Kawahara
  • Publication number: 20110114934
    Abstract: The present invention relates to a novel anthracene derivative and an organic electronic device using the same. The anthracene derivative can act as a hole injecting, hole transporting, electron injecting and transporting, or light emitting material in an organic light emitting device and an organic electronic device. In particular, the anthracene derivative can act as a light emitting host. The organic electronic device according to the present invention has excellent characteristics in views of efficiency, the driving voltage, and the stability.
    Type: Application
    Filed: July 10, 2009
    Publication date: May 19, 2011
    Inventors: Kong-Kyeom Kim, Se-Hwan Son, Dae-Woong Lee, Sang-Young Jeon, Hye-Young Jang
  • Publication number: 20110108411
    Abstract: Methods for labeling a substrate using a hetero-Diels-Alder reaction are disclosed. The hetero-Diels-Alder reaction includes the reaction of an o-quinone methide (e.g., an o-naphthoquinone methide) with a polarized olefin to form a hetero-Diels-Alder adduct. The o-quinone methide or the polarized olefin can be attached to a surface of a substrate, and the other of the o-quinone methide or the polarized olefin can include a detectable label. The o-quinone methide can conveniently be generated by irradiation of a precursor compound, preferably in an aqueous solution, suspension, or dispersion.
    Type: Application
    Filed: November 12, 2010
    Publication date: May 12, 2011
    Inventors: VLADIMIR V. POPIK, Selvanathan Arumugam
  • Publication number: 20110059911
    Abstract: The present invention relates to naphthoquinone derivatives isolated from solid callus cultures from two species of the palaeotropical plant families Dioncophyllaceae and Ancistrocladaceae. It further relates to methods of their production as well as to their use as antiinfective and antitumoral pharmaceuticals.
    Type: Application
    Filed: February 6, 2009
    Publication date: March 10, 2011
    Inventors: Gerhard Bringmann, Stefan Rüdenauer, Reto Brun, Andreas Irmer, Ralf Bargou, Manik Chatterjee, Anastasia Voskobojnik
  • Publication number: 20110009574
    Abstract: A modified dimethylnaphthalene formaldehyde resin is disclosed, which is excellent in heat resistance and useful for thermosetting resins which are used for an electrical insulating material, a resin for resist, a semiconductor sealing resin, an adhesive for printed wiring board, a matrix resin for electrical laminate or prepreg to be mounted in electrical instruments, electronic instruments, industrial instruments, etc.
    Type: Application
    Filed: December 4, 2008
    Publication date: January 13, 2011
    Applicant: Mitsubishi Gas Chemical Company, Inc.
    Inventors: Seiji Kita, Masashi Ogiwara, Mitsuharu Kitamura, Dai Oguro, Gou Higashihara
  • Publication number: 20110004024
    Abstract: The present invention relates the use of 2,3-dihalonaphthoquinone compounds of Formula I wherein R1 and R2 are leaving groups like halogens selected from the group comprising Cl, Br, I and F and the R1 and R2 may be the same halogen or may contain different halogen groups, or sulphonyl groups, for making napthoquinone compounds of Formula IA wherein X is any aryl, heteroaryl, alkyl, cyclohexyl, substituted cylohexyl groups and the like.
    Type: Application
    Filed: March 6, 2009
    Publication date: January 6, 2011
    Applicant: ALKEM LABORATORIES LIMITED
    Inventors: Sanjay Sukumar Saralya, Shashikumar Hiriyalu Somashekar, Shashiprabha, Shridhara Kanakamajalu, Koottungalmadhom Ramaswamy Ranganathan, Veerasamy Ananthalakshmi, Govindarajalu Jeyaraman, Kothapalli Sundarraja Rao, Kuppuswamy Nagarajan
  • Publication number: 20100316631
    Abstract: The present disclosure describes the design and synthesis of a novel class of water soluble curcumin-based compounds. These water soluble curcumin-based compounds are shown to provide superior cell killing activity and exhibit increased and cell internalization solubility in aqueous solutions as compared to the free (unconjugated) curcumin. The present disclosure provides compositions for the treatment or prevention of a variety of disease states or conditions, such as but not limited to, cancer, other cell hyperproliferative disorders and chronic inflammatory conditions, said compositions comprising a water soluble curcumin-based compound.
    Type: Application
    Filed: October 19, 2007
    Publication date: December 16, 2010
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventor: Ahmad Safavy
  • Patent number: 7847127
    Abstract: Disclosed herein is a novel process for preparation of atovaquone. The process includes reacting 1,4-naphthoquinone with trans-4-(4-chlorophenyl) cyclohexane carboxylic acid followed by halogenation to obtain a dihalo-compound. Further, dehydrohalogenation of the dihalo-compound produces a monohalogeno-compound which under goes hydrolysis to produce atovaquone. The invention also discloses atovaquone in a substantially pure and well defined polymorphic form designated as “Form IPCA-ATO,” and the preparation thereof.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: December 7, 2010
    Assignee: IPCA Laboratories Limited
    Inventors: Ashok Kumar, Suneel Yeshwant Dike, Pramil Kumar Mathur, Nellithanath Thankachen Byju, Brajesh Sharma, Swapnil Shreekant Kore, Vitthal Suryabhan Buchude, Dharmendra Singh
  • Publication number: 20100267781
    Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
    Type: Application
    Filed: April 14, 2010
    Publication date: October 21, 2010
    Applicant: Burnham Institute for Medical Research
    Inventor: Maurizio Pellechia